Biocompatibility in hemodialysis: clinical relevance in 1995.
Hemodialysis therapy for end-stage renal disease is still empirical even after more than 30 years of experience. Although long-term survival can now be assured in selected patients, clinical results tend to be disappointing. Hemodialysis therapy needs to be improved. Zealots of the biocompatibility school believe that this improvement will come from reducing undesirable consequences of blood membrane interaction, particularly complement activation. However, there is controversy over the clinical meaningfulness of biocompatibility when exclusively related to blood membrane interactions. Another dimension needs to be added, namely ultrapure dialysate to avoid subclinical chronic effects of activation of the cytokine cascade by bacterial fragments present in dialysate. While the pathogenesis of acute anaphylactoid reactions are understood and largely preventable, the relation of the chronic syndromes such as amyloidosis to the use of a particular membrane remain unproven. Prospective studies that will occupy at least a decade will be necessary to decide these issues.
Shaldon
S
S
Department of Nephrology, University Hospital, Nimes, France.
Koch
K M
KM
D001427:Bacterial Toxins / Q000276:immunology; D001672:Biocompatible Materials; D001769:Blood; D016207:Cytokines / Q000276:immunology; D004340:Drug Contamination; D015312:Hemodialysis Solutions; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000295:instrumentation* / Q000639:trends; D015996:Survival Rate
D001427:Bacterial Toxins; D001672:Biocompatible Materials; D016207:Cytokines; D015312:Hemodialysis Solutions; D008567:Membranes, Artificial